ABU DHABI, UAE — Thrombolytic treatment with recombinant human pro-urokinase was non-inferior to alteplase in achieving an excellent functional outcome in acute ischemic stroke but showed a ...

Medindia neither buys nor sells drugs. Urokinase (Urolyte) is an enzyme (thrombolytic agent), prescribed for deep vein thrombosis, heart attack, pulmonary embolism and peripheral vascular occlusion.

The effectiveness of alteplase and urokinase in restoring adequate hemodialysis blood-flow rates was examined. A retrospective review of the medical records of hemodialysis patients with central ...

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that key opinion leader (“ KOL ”) collaborators are presenting results ...

Shares of Monopar Therapeutics (NASDAQ:MNPR) shot up 60% in early trading Thursday after the biopharmaceuticals company reported encouraging preclinical data for its MNPR-101 program. The drug ...

The most common clot-busting drugs include Activase (alteplase), Streptase (streptokinase), and Kinlytic (urokinase). Surgery ...

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

The main flavonol of green tea, epigallocatechin-3-gallate (EGCG), inhibits urokinase 2, one of the hydrolases implicated in tumor invasion. Moreover, green tea consumption by mice significantly ...

Monopar’s presentation, accepted as a “Top-Rated Oral Presentation” within the Scientific Program, illustrates the potential of the urokinase plasminogen activator receptor (uPAR ...

urokinase plasminogen activator surface receptor, and fibroblast growth factor 23), while growth differentiation factor 15 had a stronger relationship with MI in women than in men. "The proteins ...

the Company received regulatory clearance in Australia to commence a first-in-human Phase 1a therapeutic clinical trial of its novel urokinase plasminogen activator receptor (uPAR)-targeted ...